Home | Screening data | Screen comparisons | Search for compounds | Structure search

Compound InformationSONAR Target prediction
Name:

ORLISTAT

Unique Identifier:SPE01504300
MolClass: Checkout models in ver1.5 and ver1.0
Molecular Formula:
Molecular Weight:442.314 g/mol
X log p:1.777  (online calculus)
Lipinksi Failures1
TPSA69.67
Hydrogen Bond Donor Count:0
Hydrogen Bond Acceptors Count:6
Rotatable Bond Count:24
Canonical Smiles:CCCCCCCCCCCC(CC1OC(=O)C1CCCCCC)OC(=O)C(CC(C)C)NC=O
Source:synthetic
Therapeutics:reversible lipase inhibitor, antiobesity
Generic_name:Orlistat
Chemical_iupac_name:1-(3-hexyl-4-oxo-oxetan-2-yl)tridecan-2-yl 2-formylamino-4-methyl-pentanoate
Drug_type:Approved Drug
Pharmgkb_id:PA450714
Drugbank_id:APRD00255
H2o_solubility:Practically insoluble
Logp:8.533
Isoelectric_point:No pKa within the physiological pH range.
Cas_registry_number:96829-58-2
Drug_category:Anti-Obesity Agents; Enzyme Inhibitors; ATC:A08AB01
Indication:For obesity management including weight loss and weight maintenance when used in
conjunction with a reduced-calorie diet. Also used to reduce the risk for weight
regain after prior weight loss.
Pharmacology:Orlistat is a lipase inhibitor for obesity management that acts by inhibiting the
absorption of dietary fats. At the recommended therapeutic dose of 120 mg three
times a day, orlistat inhibits dietary fat absorption by approximately 30%. It works
by inhibiting pancreatic lipase, an enzyme that breaks down fat in the intestine.
Without this enzyme, fat from the diet is excreted undigested, and not absorbed by
the body. Because some vitamins are fat soluble, the effect of orlistat is to reduce
their body absorption. Therefore the drug should only be taken in conjuction with
fatty meals, and a multivitamin tablet containing these vitamins (D E K and
beta-carotene) should be taken once a day, at least 2 hours before or after taking
the drug. In the March 15, 2004 issue of Cancer Research,[1] Steven J. Kridel et al.
state that orlistat may also inhibit growth of prostate cancer, and in theory may be
useful in treating other cancers, by interfering with the metabolism of fats.
Mechanism_of_action:Orlistat is a reversible inhibitor of lipases. It exerts its therapeutic activity in
the lumen of the stomach and small intestine by forming a covalent bond with the
active serine residue site of gastric and pancreatic lipases. The inactivated
enzymes are thus unavailable to hydrolyze dietary fat in the form of triglycerides
into absorbable free fatty acids and monoglycerides. As undigested triglycerides are
not absorbed, the resulting caloric deficit may have a positive effect on weight
control.
Organisms_affected:Humans and other mammals

Found: 192 nonactive as graph: single | with analogs [1] << Back 191 192 Next >> [192]
Species: 4932
Condition: YPT6
Replicates: 2
Raw OD Value: r im 0.4164±0.0168999
Normalized OD Score: sc h 1.0879±0.0047164
Z-Score: 0.7316±0.0540672
p-Value: 0.464728
Z-Factor: -0.887481
Fitness Defect: 0.7663
Bioactivity Statement: Nonactive
Experimental Conditions
Library:Spectrum
Plate Number and Position:20|E7
Drug Concentration:50.00 nM
OD Absorbance:600 nm
Robot Temperature:27.20 Celcius
Date:2006-02-22 YYYY-MM-DD
Plate CH Control (+):0.040625±0.00121
Plate DMSO Control (-):0.35515±0.01336
Plate Z-Factor:0.8763
png
ps
pdf

DBLink | Rows returned: 5
4599 1-(3-hexyl-4-oxo-oxetan-2-yl)tridecan-2-yl 2-formamido-4-methyl-pentanoate
3034010 [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-oxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methyl-pentanoate
5284600 [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-oxetan-2-yl]tridecan-2-yl] 2-formamido-4-methyl-pentanoate
6710691 [(2S)-1-[(2R,3S)-3-hexyl-4-oxo-oxetan-2-yl]tridecan-2-yl] (2R)-2-formamido-4-methyl-pentanoate
15973425 [(2S)-1-[(2S,3S)-3-(5-methylhexyl)-4-oxo-oxetan-2-yl]tridecan-2-yl] (2R)-2-formamido-4-methyl-pentanoate

internal high similarity DBLink | Rows returned: 0

active | Cluster 4053 | Additional Members: 2 | Rows returned: 0

Service provided by the Mike Tyers Laboratory